These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38394537)

  • 1. Association between patient adherence and treat-to-target in gout: A cross-sectional study.
    Hu S; He S; Zhang J; Ma W; Geng H; Zhan Z; Yao X; Zhong L; Wei J; Qiu X; Jia E
    Medicine (Baltimore); 2024 Feb; 103(8):e37228. PubMed ID: 38394537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to gout management recommendations of Chinese patients.
    Sheng F; Fang W; Zhang B; Sha Y; Zeng X
    Medicine (Baltimore); 2017 Nov; 96(45):e8532. PubMed ID: 29137059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
    Son CN; Stewart S; Su I; Mihov B; Gamble G; Dalbeth N
    Semin Arthritis Rheum; 2021 Aug; 51(4):677-684. PubMed ID: 34139520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering therapy adherence and the association with medication beliefs, self-efficacy, depression, anxiety, and COVID-19 pandemic-related concern in Chinese gout patients: a cross-sectional study.
    Yin R; Lu J; Xu Z; Yan Q; Wang M; Xu R
    Psychol Health Med; 2023; 28(7):1698-1708. PubMed ID: 37322811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol for chronic gout.
    Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat to target in gout.
    Perez-Ruiz F; Moreno-Lledó A; Urionagüena I; Dickson AJ
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i20-i26. PubMed ID: 29272512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment.
    Slot O
    Scand J Rheumatol; 2018 May; 47(3):194-197. PubMed ID: 28891365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence with urate-lowering therapies for the treatment of gout.
    Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
    Hill-McManus D; Soto E; Marshall S; Lane S; Hughes D
    Br J Clin Pharmacol; 2018 Jan; 84(1):142-152. PubMed ID: 28888218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
    Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
    Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic gout: Barriers to effective management.
    Rogenmoser S; Arnold MH
    Aust J Gen Pract; 2018 Jun; 47(6):351-356. PubMed ID: 29966174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.
    Abhishek A; Jenkins W; La-Crette J; Fernandes G; Doherty M
    Rheumatology (Oxford); 2017 Apr; 56(4):529-533. PubMed ID: 28082620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treat-to-target (T2T) recommendations for gout.
    Kiltz U; Smolen J; Bardin T; Cohen Solal A; Dalbeth N; Doherty M; Engel B; Flader C; Kay J; Matsuoka M; Perez-Ruiz F; da Rocha Castelar-Pinheiro G; Saag K; So A; Vazquez Mellado J; Weisman M; Westhoff TH; Yamanaka H; Braun J
    Ann Rheum Dis; 2017 Apr; 76(4):632-638. PubMed ID: 27658678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.